Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-570-0
CAS number: 108-30-5
Review of data summarized, based on 5
summary of studies on cyclic anhydrides demonstrate that cyclic acid
anhydrides display low systemic bioavailability after dermal exposure
but increased absorption rates after inhalation exposure (> 85% of
inhaled dose). Cyclic acid anhydrides bind to plasma proteins and
haemoglobin and the primary binding amino acid appears to be lysine. The
half-time of methyl hexahydropthalic anhydride adducts was 20 days.
Cyclic acid anhydrides are hydrolysed to corresponding dicarboxylic
acids and effectively excreted in urine. The urinary half-time for the
dicarboxylic acid of phthalic anhydride was 14 h, whereas half-times for
the dicarboxylic acids of hexahydrophthalic anhydride, methyl
hexahydrophthalicanhydride, and methyl tetrahydrophthalic anhydride were
generally shorter (between 2 and 7 h).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again